Compare common side effects, interactions, warnings, and more.
Farxiga
*image for illustrative purpose only
Ozempic
Farxiga
*image for illustrative purpose only
Ozempic
Farxiga® (dapagliflozin) is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. It lowers blood sugar by promoting glucose excretion through the urine. Farxiga is indicated for reducing the risk of estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in adults with chronic kidney disease. Additionally, it reduces the risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure. It decreases heart failure hospitalization risk in adults with type 2 diabetes and cardiovascular disease or risk factors. Farxiga also aids in improving glycemic control alongside diet and exercise in adults and children aged 10 and older with type 2 diabetes. Common side effects include urinary and genital infections, and it may cause rare but serious conditions like ketoacidosis and dehydration.
Ozempic® (semaglutide) is an injectable medication used to improve blood sugar control in adults with type 2 diabetes, to reduce the risk of major cardiovascular events in individuals with established heart disease, and to reduce the risk of kdiney problems in certain populations. It works by mimicking the hormone glucagon-like peptide-1 (GLP-1), which increases insulin secretion, decreases glucagon release, and slows gastric emptying. Administered once weekly, Ozempic is often part of a comprehensive treatment plan that includes diet and exercise. Common side effects include nausea, vomiting, diarrhea, and abdominal pain, and it should be used with caution in patients with a history of pancreatitis.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Glucagon-like peptide-1 (GLP-1) receptor agonist
Farxiga (dapagliflozin) is indicated:
To reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression
To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure
To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors
As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus
Ozempic (semaglutide) is indicated:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease
Typically taken orally once daily
Comes in 5 mg and 10 mg tablets
Typically taken as an injection once weekly
Comes in single-patient-use pens that deliver 0.25 mg, 0.5 mg, 1 mg, or 2 mg per injection
Most common adverse reactions (5% or greater incidence) were:
Female genital fungal infections
Inflammation of the nasal cavities and back of the throat
Urinary tract infections
The most common adverse reactions, reported in ≥5% of patients are:
Nausea
Vomiting
Diarrhea
Abdominal pain
Constipation
History of serious hypersensitivity reaction to dapagliflozin or any of the excipients in Farxiga
See the Full Prescribing Information for information on drug interactions and interference of Farxiga with laboratory tests
Personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2
Serious hypersensitivity reaction to semaglutide or any of the excipients in Ozempic
Drug interactions: Ozempic delays gastric emptying and may impact the absorption of concomitantly administered oral medications
Diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis
Volume depletion
Urosepsis and pyelonephritis
Low blood sugar
Necrotizing fasciitis of the perineum (Fournier’s gangrene)
Genital fungal infections
Pregnancy: Potential risk to a fetus especially during the second and third trimesters
Lactation: Not recommended when breastfeeding
Pancreatitis
Diabetic retinopathy complications
Never share an Ozempic pen between patients, even if the needle is changed
Low blood sugar: Concomitant use with an insulin secretagogue or insulin may increase the risk of low blood sugar, including severe low blood sugar
Acute kidney injury
Hypersensitivity reactions
Acute gallbladder disease
Females and males of reproductive potential: Discontinue Ozempic in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide
WARNING: RISK OF THYROID C-CELL TUMORS
In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
*This information is from the label for brand name Farxiga®. See the Full Prescribing Information for more complete information.
*This information is from the label for brand name Ozempic®. See the Full Prescribing Information for more complete information. Semaglutide, the active ingredient in Ozempic, may also be the active ingredient in other medications, and this information may not be accurate for all medications that include the active ingredient semaglutide.
The information provided here is NOT MEDICAL ADVICE and is for informational and educational purposes only. The drug comparison tool does not determine eligibility for medications or treatments provided via the Hims/Hers platform. Consultation with a healthcare provider is required to assess suitability for any medical treatment based on individual health and medical history. All product names and associated trademarks are the property of their respective owners.